Complete inhibition of canonical IKK/NF-κB signaling by NEMO deficiency prevented the development of SCLC, most likely by sensitizing RB1-TP53 double-deficient cells to death, whereas RelA knockout had a less pronounced effect in delaying tumor development and progression. Here, TP53 is linked to neoplasm.